NEUPOGEN is a Intravenous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Amgen Inc. The primary component is Filgrastim.
Product ID | 55513-546_37a4c6e3-f99d-4526-b43a-82bb8d861c33 |
NDC | 55513-546 |
Product Type | Human Prescription Drug |
Proprietary Name | NEUPOGEN |
Generic Name | Filgrastim |
Dosage Form | Injection, Solution |
Route of Administration | INTRAVENOUS; SUBCUTANEOUS |
Marketing Start Date | 1997-04-07 |
Marketing Category | BLA / BLA |
Application Number | BLA103353 |
Labeler Name | Amgen Inc |
Substance Name | FILGRASTIM |
Active Ingredient Strength | 480 ug/1.6mL |
Pharm Classes | Granulocyte Colony-Stimulating Factor [CS], Granulocyte-Macrophage Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 1997-04-07 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA103353 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 1997-04-07 |
Marketing Category | BLA |
Application Number | BLA103353 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 1997-04-07 |
Ingredient | Strength |
---|---|
FILGRASTIM | 480 ug/1.6mL |
SPL SET ID: | 97cc73cc-b5b7-458a-a933-77b00523e193 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
55513-209 | NEUPOGEN | Filgrastim |
55513-530 | NEUPOGEN | Filgrastim |
55513-546 | NEUPOGEN | Filgrastim |
55513-924 | NEUPOGEN | Filgrastim |
70121-1568 | RELEUKO | Filgrastim |
70121-1569 | RELEUKO | Filgrastim |
70121-1570 | RELEUKO | Filgrastim |
70121-1571 | RELEUKO | Filgrastim |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
NEUPOGEN 73820719 1597117 Live/Registered |
AMGEN INC. 1989-08-05 |
NEUPOGEN 73749907 1607975 Live/Registered |
AMGEN INC. 1988-09-02 |